Contact Us
Drug Search Results
More Filters [+]

BBO-11818

Alternative Names: BBO-11818, BBO11818
Latest Update: 2024-07-11
Latest Update Note: News Article

Product Description

BBO-11818, a pan-KRAS inhibitor that targets both the ON and OFF states of KRASG12X for which BBOT expects to file an IND in early 2025. (Sourced from: https://bridgebio.com/news/bridgebio-launches-bridgebio-oncology-therapeutics-bbot-with-200m-of-private-external-capital-to-accelerate-the-development-of-its-novel-precision-oncology-pipeline/)

Mechanisms of Action: KRAS Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: BridgeBio
Company Location: PALO ALTO CA 94301
Company CEO: Neil Kumar
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BBO-11818

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title

07/11/2024

News Article

 KRAS Inhibitors Drugs Market Forecast Clinical Trials Companies FDA Approval Insight

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions